[go: up one dir, main page]

CL2008001230A1 - Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis. - Google Patents

Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.

Info

Publication number
CL2008001230A1
CL2008001230A1 CL2008001230A CL2008001230A CL2008001230A1 CL 2008001230 A1 CL2008001230 A1 CL 2008001230A1 CL 2008001230 A CL2008001230 A CL 2008001230A CL 2008001230 A CL2008001230 A CL 2008001230A CL 2008001230 A1 CL2008001230 A1 CL 2008001230A1
Authority
CL
Chile
Prior art keywords
angiogenesis
inhibition
preparation
treatment
pharmaceutical composition
Prior art date
Application number
CL2008001230A
Other languages
English (en)
Inventor
Joseph Sajan
Dean Dally Robert
Huang Jianping
Alan Shepherd Timothy
L Holst Christian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2008001230A1 publication Critical patent/CL2008001230A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPUESTOS DE LA FÓRMULA (1): DONDE R', R2, R4, R5, Z1, Y Z2 SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA Y PLIEGO; INHIBIDORES DE QUINASA P70 S6; COMPOSICIÓN FARMACÉUTICA; Y USO EN LA PREPARACIÓN DE MEDICAMENTOS ÚTILES EN<br /> EL TRATAMIENTO DE ADENOCARCINOMA DEL COLON E INHIBICIÓN DE ANGIOGÉNESIS.
CL2008001230A 2007-05-11 2008-04-29 Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis. CL2008001230A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
CL2008001230A1 true CL2008001230A1 (es) 2009-05-22

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001230A CL2008001230A1 (es) 2007-05-11 2008-04-29 Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.

Country Status (33)

Country Link
US (2) US8093383B2 (es)
EP (1) EP2148880B1 (es)
JP (1) JP5503532B2 (es)
KR (1) KR101088219B1 (es)
CN (1) CN101679439B (es)
AR (1) AR066344A1 (es)
AU (1) AU2008251692B2 (es)
BR (1) BRPI0811212A2 (es)
CA (1) CA2687265C (es)
CL (1) CL2008001230A1 (es)
CO (1) CO6241109A2 (es)
CR (1) CR11106A (es)
DK (1) DK2148880T3 (es)
DO (1) DOP2009000257A (es)
EA (1) EA016445B1 (es)
EC (1) ECSP099721A (es)
ES (1) ES2483726T3 (es)
GT (1) GT200900292A (es)
HR (1) HRP20140611T1 (es)
IL (1) IL201564A (es)
MA (1) MA31433B1 (es)
MX (1) MX2009012075A (es)
MY (1) MY154898A (es)
NZ (1) NZ580423A (es)
PE (1) PE20090887A1 (es)
PL (1) PL2148880T3 (es)
PT (1) PT2148880E (es)
RS (1) RS53451B (es)
SI (1) SI2148880T1 (es)
TN (1) TN2009000446A1 (es)
TW (1) TWI423805B (es)
UA (1) UA99284C2 (es)
WO (1) WO2008140947A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2010019762A1 (en) * 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
EP2355820A1 (en) * 2008-11-11 2011-08-17 Eli Lilly and Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
MX2011005002A (es) * 2008-11-11 2011-05-25 Lilly Co Eli Inhibidor de p70 s6 quinasa y terapia de combinacion de inhibidor del receptor de egfr.
PL2396307T3 (pl) 2009-02-11 2015-03-31 Merck Patent Gmbh Nowe aminowe azaheterocykliczne karboksyamidy
ES2654332T3 (es) 2009-08-07 2018-02-13 Merck Patent Gmbh Nuevos compuestos azaheterocíclicos
EA020151B1 (ru) * 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
KR101942212B1 (ko) 2010-02-03 2019-01-24 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제자에 대한 민감성 예측 바이오마커로서 ｌｋｂ1 돌연변이의 동정
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
BR112013002212A2 (pt) 2010-07-29 2017-09-26 Merck Patent Gmbh carboxamidas aza-heterocíclicas de aminas cíclicas
WO2012069146A1 (en) 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines
BR112014005468A2 (pt) 2011-09-12 2017-03-21 Merck Patent Gmbh derivados de aminopiridina para uso como moduladores de atividade quinase
LT2755965T (lt) 2011-09-12 2017-11-10 Merck Patent Gmbh Naujieji imidazolo aminai kaip kinazės aktyvumo moduliatoriai
MX2015002887A (es) 2012-09-06 2015-07-06 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2013344552B2 (en) 2012-11-16 2018-03-15 Xiaoling Chen Novel heterocyclic derivatives as modulators of kinase activity
ES2656096T3 (es) 2012-11-16 2018-02-23 Merck Patent Gmbh Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
EP2925747B1 (en) 2012-11-29 2020-06-24 Merck Patent GmbH Azaquinazoline carboxamide derivatives
KR20150124957A (ko) * 2013-03-11 2015-11-06 메르크 파텐트 게엠베하 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체
EP2986298A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Treatment of cancer with dihydropyrazino-pyrazines
US9359364B2 (en) 2013-04-17 2016-06-07 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
SG10201801965RA (en) 2013-04-17 2018-04-27 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
SG11201508302PA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
HK1221144A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CN105407892B (zh) 2013-05-29 2019-05-07 西格诺药品有限公司 一种化合物的药物组合物、其固体形式及它们的使用方法
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102410696B1 (ko) 2014-04-03 2022-06-17 메르크 파텐트 게엠베하 암 치료법의 조합
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
EP4243819A1 (en) 2020-11-16 2023-09-20 Merck Patent GmbH Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1750727A2 (en) * 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
NZ580423A (en) 2012-02-24
CR11106A (es) 2010-04-12
SI2148880T1 (sl) 2014-07-31
CA2687265C (en) 2012-12-04
CA2687265A1 (en) 2008-11-20
TWI423805B (zh) 2014-01-21
JP5503532B2 (ja) 2014-05-28
AU2008251692B2 (en) 2012-10-11
US20120071490A1 (en) 2012-03-22
EA200971051A1 (ru) 2010-06-30
CN101679439B (zh) 2013-09-11
HK1140767A1 (en) 2010-10-22
ES2483726T3 (es) 2014-08-07
MX2009012075A (es) 2009-11-19
PL2148880T3 (pl) 2014-10-31
UA99284C2 (ru) 2012-08-10
IL201564A0 (en) 2010-05-31
EP2148880B1 (en) 2014-05-28
AU2008251692A1 (en) 2008-11-20
IL201564A (en) 2014-08-31
TN2009000446A1 (en) 2011-03-31
KR20100005710A (ko) 2010-01-15
PT2148880E (pt) 2014-08-28
DOP2009000257A (es) 2010-03-31
RS53451B (sr) 2014-12-31
EA016445B1 (ru) 2012-05-30
ECSP099721A (es) 2009-12-28
CN101679439A (zh) 2010-03-24
US20090163714A1 (en) 2009-06-25
MA31433B1 (fr) 2010-06-01
CO6241109A2 (es) 2011-01-20
HRP20140611T1 (hr) 2014-08-15
US8093383B2 (en) 2012-01-10
WO2008140947A1 (en) 2008-11-20
DK2148880T3 (da) 2014-06-16
JP2010526814A (ja) 2010-08-05
MY154898A (en) 2015-08-28
KR101088219B1 (ko) 2011-11-30
TW200848053A (en) 2008-12-16
BRPI0811212A2 (pt) 2014-10-29
PE20090887A1 (es) 2009-07-13
GT200900292A (es) 2011-06-24
AR066344A1 (es) 2009-08-12
EP2148880A1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
MX2010003668A (es) Derivados de purina sustituidas con primidina.
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
AU2009282962A8 (en) Compounds as kinase inhibitors
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
CL2011000195A1 (es) Compuestos derivados de 5-alquinil-pirimidina, inhibidores de quinasas; composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer.
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.